Growing levels of resistance to available antimicrobial medicines are causing tens of thousands of deaths each year across the world. By 2050, the overall costs associated with antimicrobial resistance (AMR) could reduce global gross domestic product (GDP) by 2 to 3.5%. One concern is the development of resistance to the carbapenem antibiotics among Gram-negative bacteria, in particular, the carbapenemase-producing Enterobacteriaceae (CPE). Enterobacteriaceae are the source of community- and hospital-acquired infections…